Celldex Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Celldex Therapeutics reported third-quarter 2022 financial results, revealing a net loss of $26.8 million, or $0.57 per share. The company had $323.5 million in cash assets, a decrease from the previous quarter. Revenue for Q3 was $0.4 million, down from $0.7 million in the same period last year. Significant clinical advancements include the initiation of Phase 2 studies for barzolvolimab, with promising early data showing symptom improvements in chronic urticaria patients. The company expects ongoing data releases and has plans for new bispecific antibody trials in 2023.
- Initiated Phase 2 studies for barzolvolimab, showing potential in chronic urticaria.
- Strong balance sheet with $323.5 million in cash, sufficient through 2025.
- Positive interim data from barzolvolimab studies, indicating symptom relief.
- Q3 net loss increased to $26.8 million, compared to $20.5 million in Q3 2021.
- Revenue decreased to $0.4 million from $0.7 million year-over-year.
- R&D expenses rose significantly to $21.6 million, impacting financial stability.
- Multiple clinical-stage programs on track for data updates in upcoming months -
HAMPTON, N.J., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the third quarter ended September 30, 2022 and provided a corporate update.
“Celldex continued to execute towards our clinical and corporate milestones, making strong progress across multiple programs; importantly, this includes the initiation of our Phase 2 studies in chronic spontaneous and chronic inducible urticaria this past summer. As we near the close of 2022 and look to 2023, we anticipate a consistent stream of data readouts from the barzolvolimab program, starting in December with additional data from our Phase 1 study in chronic inducible urticaria,” said Anthony Marucci, Co-founder, President and Chief Executive Officer of Celldex Therapeutics. “We are also enthusiastic about the potential of our bispecific platform and believe our strategic updates including the development of CDX-585, our ILT4 and PD-(L)1 bispecific antibody, which is expected to enter the clinic in 2023, will drive value for this platform.”
“In summary, our recent advances of the barzolvolimab program, development of our bispecific platform, and strong balance sheet continue to position us very well to execute across our upcoming key clinical milestones. We look forward to continued momentum across the company for the rest of the year and providing updates in the coming months,” concluded Mr. Marucci.
Recent Program Highlights
Barzolvolimab - KIT Inhibitor Program
Barzolvolimab is a humanized monoclonal antibody developed by Celldex that binds the KIT receptor with high specificity and potently inhibits its activity. The KIT receptor tyrosine kinase is expressed in a variety of cells, including mast cells, which mediate inflammatory responses such as hypersensitivity and allergic reactions. KIT signaling controls the differentiation, tissue recruitment, survival and activity of mast cells.
- In June and July 2022, Celldex announced that the first patients have been dosed in the Phase 2 clinical studies of barzolvolimab for the treatment of Chronic Spontaneous Urticaria (CSU) and the two most common forms of chronic inducible urticaria (CIndU) - cold urticaria (ColdU) and symptomatic dermographism (SD). These randomized, double-blind, placebo-controlled, parallel group Phase 2 studies are evaluating the efficacy and safety profile of multiple dose regimens of barzolvolimab in patients who remain symptomatic despite antihistamine therapy, to determine the optimal dosing strategies.
- On June 30, Celldex reported interim data from the barzolvolimab multiple dose Phase 1b study in CSU which were presented as a late-breaking electronic poster presentation as part of the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress 2022. The Company has since completed enrollment to the 3 and 4.5 mg/kg dose groups and plans to present 12-week treatment data from these dose groups in February 2023.
- EAACI 2022 Data Summary:
- Barzolvolimab was well tolerated with a favorable safety profile; effects of multiple dose administration were consistent with observations in single dose studies. Barzolvolimab resulted in rapid, marked and durable responses in patients with moderate to severe CSU refractory to antihistamines, including patients with prior omalizumab treatment.
- Mean reduction from baseline in urticaria activity (UAS7) of
66.6% in all patients in the 1.5 mg/kg dose group (n=8) at week 12 and75.1% in all patients in the 3 mg/kg dose group (n=9) at week 8 (reflects only one dose), demonstrating clinically meaningful symptom improvements for patients. - Complete response (UAS7=0) of
57.1% in the 1.5 mg/kg dose group at week 12 and44.4% at week 8 (reflects only one dose) in the 3 mg/kg dose group which is a key therapeutic goal. 75% well-controlled disease by Urticaria Control Test (UCT) in the 1.5 mg/kg dose group at week 12 and83.3% in the 3 mg/kg dose group at week 8 (reflects only one dose).- Tryptase suppression paralleled symptom improvement, demonstrating the impact of mast cell depletion on CSU disease activity.
- Celldex has completed enrollment in the barzolvolimab Phase 1b open label study in chronic inducible urticaria. The Company plans to present data from the 1.5 mg/kg cold urticaria cohort and long-term follow up from the 3 mg/kg symptomatic dermographism and cold urticaria cohorts in December. Patient follow up continues in the cholinergic cohort and is planned for presentation in mid-2023.
- Celldex continues to enroll patients in the barzolvolimab Phase 1b multi-center, randomized, double-blind, placebo-controlled study in patients with prurigo nodularis (PN), a chronic skin disease characterized by the development of hard, intensely itchy (pruritic) nodules on the skin.
- Celldex plans to initiate a Phase 2 international trial of barzolvolimab in eosinophilic esophagitis (EoE), the most common type of eosinophilic gastrointestinal disease, in the first half of 2023. The Company is finalizing clinical study design and completing the chronic toxicology study which will support study initiation in the United States.
Bispecific Antibody Platform
CDX-585 – Bispecific ILT4 & PD-(L)1
CDX-585 combines highly active PD-1 blockade with anti-ILT4 blockade to overcome immunosuppressive signals in T cells and myeloid cells. ILT4 is emerging as an important immune checkpoint on myeloid cells.
- CDX-585 is currently completing CMC and IND-enabling activities and is expected to enter the clinic in 2023.
CDX-527 – Bispecific PD-L1 & CD27
CDX-527 utilizes the Company’s proprietary highly active anti-PD-L1 and CD27 human antibodies to couple CD27 co-stimulation with blockade of the PD-L1/PD-1 pathway.
- The standard of care in ovarian cancer continues to evolve, making drug development in this indication more challenging. With multiple clinical trials actively recruiting in ovarian cancer, enrollment to the expansion cohort in patients with checkpoint naïve ovarian cancer (n=8) did not meet the Company’s internal timelines and a review of the results to date also did not meet internal hurdles for proceeding. Given the evolving environment and Celldex’s pipeline and resource priorities, the Company has decided to discontinue the program.
Third Quarter 2022 Financial Highlights and 2022 Guidance
Cash Position: Cash, cash equivalents and marketable securities as of September 30, 2022 were
Revenues: Total revenue was
R&D Expenses: Research and development (R&D) expenses were
G&A Expenses: General and administrative (G&A) expenses were
Changes in Fair Value Remeasurement of Contingent Consideration: The Company recorded a
Litigation Settlement Related Loss: The Company recorded a one-time loss of
Net Loss: Net loss was
Financial Guidance: Celldex believes that the cash, cash equivalents and marketable securities at September 30, 2022 are sufficient to meet estimated working capital requirements and fund planned operations through 2025.
About Celldex Therapeutics, Inc.
Celldex is a clinical stage biotechnology company dedicated to developing monoclonal and bispecific antibodies that address devastating diseases for which available treatments are inadequate. Our pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with inflammatory diseases and many forms of cancer. Visit www.celldex.com.
Forward Looking Statement
This release contains "forward-looking statements" made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words such as "believes," "expects," "anticipates," "intends," "will," "may," "should," or similar expressions. These forward-looking statements reflect management's current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct or that those goals will be achieved, and you should be aware that actual results could differ materially from those contained in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, our ability to successfully complete research and further development and commercialization of Company drug candidates, including barzolvolimab (also referred to as CDX-0159), in current or future indications; the uncertainties inherent in clinical testing and accruing patients for clinical trials; our limited experience in bringing programs through Phase 3 clinical trials; our ability to manage and successfully complete multiple clinical trials and the research and development efforts for our multiple products at varying stages of development; the effects of the outbreak of COVID-19 on our business and results of operations; the availability, cost, delivery and quality of clinical materials produced by our own manufacturing facility or supplied by contract manufacturers, who may be our sole source of supply; the timing, cost and uncertainty of obtaining regulatory approvals; the failure of the market for the Company's programs to continue to develop; our ability to protect the Company's intellectual property; the loss of any executive officers or key personnel or consultants; competition; changes in the regulatory landscape or the imposition of regulations that affect the Company's products; our ability to continue to obtain capital to meet our long-term liquidity needs on acceptable terms, or at all, including the additional capital which will be necessary to complete the clinical trials that we have initiated or plan to initiate; and other factors listed under "Risk Factors" in our annual report on Form 10-K and quarterly reports on Form 10-Q.
All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. We have no obligation, and expressly disclaim any obligation, to update, revise or correct any of the forward-looking statements, whether as a result of new information, future events or otherwise.
Company Contact
Sarah Cavanaugh
Senior Vice President, Corporate Affairs & Administration
(508) 864-8337
scavanaugh@celldex.com
Patrick Till
Meru Advisors
(484) 788-8560
ptill@meruadvisors.com
| CELLDEX THERAPEUTICS, INC. | ||||||||||||||||||
| (In thousands, except per share amounts) | ||||||||||||||||||
| Three Months | Nine Months | |||||||||||||||||
| Consolidated Statements of Operations Data | Ended September 30, | Ended September 30, | ||||||||||||||||
| 2022 | 2021 | 2022 | 2021 | |||||||||||||||
| (Unaudited) | (Unaudited) | |||||||||||||||||
| Revenues: | ||||||||||||||||||
| Product development and licensing agreements | $ | - | $ | - | $ | 30 | $ | 29 | ||||||||||
| Contracts and grants | 407 | 153 | 714 | 4,288 | ||||||||||||||
| Total revenues | 407 | 153 | 744 | 4,317 | ||||||||||||||
| Operating expenses: | ||||||||||||||||||
| Research and development | 21,572 | 13,557 | 59,359 | 38,633 | ||||||||||||||
| General and administrative | 6,531 | 5,821 | 20,596 | 14,247 | ||||||||||||||
| Intangible asset impairment | - | 3,500 | - | 3,500 | ||||||||||||||
| Gain on fair value remeasurement of contingent consideration | - | (1,901 | ) | (6,862 | ) | (1,160 | ) | |||||||||||
| Litigation settlement loss | - | - | 15,000 | - | ||||||||||||||
| Total operating expenses | 28,103 | 20,977 | 88,093 | 55,220 | ||||||||||||||
| Operating loss | (27,696 | ) | (20,824 | ) | (87,349 | ) | (50,903 | ) | ||||||||||
| Investment and other income, net | 912 | 145 | 1,511 | 313 | ||||||||||||||
| Net loss before income tax benefit | $ | (26,784 | ) | $ | (20,679 | ) | $ | (85,838 | ) | $ | (50,590 | ) | ||||||
| Income tax benefit | - | 227 | - | 227 | ||||||||||||||
| Net loss | $ | (26,784 | ) | $ | (20,452 | ) | $ | (85,838 | ) | $ | (50,363 | ) | ||||||
| Basic and diluted net loss per common share | $ | (0.57 | ) | $ | (0.45 | ) | $ | (1.83 | ) | $ | (1.21 | ) | ||||||
| Shares used in calculating basic and diluted net loss per share | 46,916 | 45,453 | 46,806 | 41,582 | ||||||||||||||
| Condensed Consolidated Balance Sheet Data | September 30, | December 31, | ||||||||||||||||
| 2022 | 2021 | |||||||||||||||||
| (Unaudited) | ||||||||||||||||||
| Assets | ||||||||||||||||||
| Cash, cash equivalents and marketable securities | $ | 323,471 | $ | 408,250 | ||||||||||||||
| Other current assets | 11,128 | 2,589 | ||||||||||||||||
| Property and equipment, net | 3,753 | 3,551 | ||||||||||||||||
| Intangible and other assets, net | 30,874 | 30,264 | ||||||||||||||||
| Total assets | $ | 369,226 | $ | 444,654 | ||||||||||||||
| Liabilities and stockholders' equity | ||||||||||||||||||
| Current liabilities | $ | 16,287 | $ | 16,528 | ||||||||||||||
| Long-term liabilities | 7,523 | 8,650 | ||||||||||||||||
| Stockholders' equity | 345,416 | 419,476 | ||||||||||||||||
| Total liabilities and stockholders' equity | $ | 369,226 | $ | 444,654 | ||||||||||||||
FAQ
What were Celldex's Q3 2022 financial results?
What is the cash position of Celldex as of September 30, 2022?
What clinical programs are currently ongoing for Celldex?
How did Celldex's revenue change in Q3 2022?
What is the financial guidance for Celldex?
